SG11201404543UA - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents
Pluripotent germ layer origin antigen presenting cancer vaccineInfo
- Publication number
- SG11201404543UA SG11201404543UA SG11201404543UA SG11201404543UA SG11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA SG 11201404543U A SG11201404543U A SG 11201404543UA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen presenting
- cancer vaccine
- germ layer
- pluripotent germ
- presenting cancer
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 238000009566 cancer vaccine Methods 0.000 title 1
- 210000001654 germ layer Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| PCT/US2013/024123 WO2013116505A1 (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404543UA true SG11201404543UA (en) | 2014-08-28 |
Family
ID=48905824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404543UA SG11201404543UA (en) | 2012-02-02 | 2013-01-31 | Pluripotent germ layer origin antigen presenting cancer vaccine |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150064217A1 (zh) |
| EP (1) | EP2809775B1 (zh) |
| JP (1) | JP2015506698A (zh) |
| KR (1) | KR20140143361A (zh) |
| CN (1) | CN104540937A (zh) |
| AU (1) | AU2013215116A1 (zh) |
| CA (1) | CA2863653A1 (zh) |
| GB (1) | GB2512558A (zh) |
| HK (2) | HK1202432A1 (zh) |
| IL (1) | IL233928A0 (zh) |
| NZ (1) | NZ628292A (zh) |
| SG (1) | SG11201404543UA (zh) |
| WO (2) | WO2013116505A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| US11291718B2 (en) * | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
| JPWO2018131659A1 (ja) * | 2017-01-11 | 2019-12-12 | 国立研究開発法人国立がん研究センター | 免疫療法剤 |
| WO2018151813A1 (en) * | 2017-02-17 | 2018-08-23 | Aivita Biomedical, Inc. | Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140796A0 (en) * | 2001-01-08 | 2002-02-10 | Hadasit Med Res Service | An autologous anti-cancer vaccine |
| BRPI0212545B8 (pt) * | 2001-09-06 | 2021-05-25 | Northwest Biotherapeutics Inc | método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t |
| CN101052709B (zh) * | 2004-10-25 | 2012-06-27 | 贝勒研究院 | 装载热激黑素瘤细胞体的树突细胞 |
| EP1912672B1 (en) * | 2005-07-29 | 2013-09-04 | Providence Health System | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| CA2700579A1 (en) * | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
-
2013
- 2013-01-31 SG SG11201404543UA patent/SG11201404543UA/en unknown
- 2013-01-31 GB GB1414403.4A patent/GB2512558A/en not_active Withdrawn
- 2013-01-31 WO PCT/US2013/024123 patent/WO2013116505A1/en active Application Filing
- 2013-01-31 CN CN201380017689.2A patent/CN104540937A/zh active Pending
- 2013-01-31 EP EP13743673.9A patent/EP2809775B1/en not_active Not-in-force
- 2013-01-31 US US14/375,966 patent/US20150064217A1/en not_active Abandoned
- 2013-01-31 KR KR1020147024678A patent/KR20140143361A/ko not_active Application Discontinuation
- 2013-01-31 AU AU2013215116A patent/AU2013215116A1/en not_active Abandoned
- 2013-01-31 JP JP2014555705A patent/JP2015506698A/ja active Pending
- 2013-01-31 WO PCT/US2013/024181 patent/WO2013116541A1/en active Application Filing
- 2013-01-31 CA CA2863653A patent/CA2863653A1/en not_active Abandoned
- 2013-01-31 NZ NZ628292A patent/NZ628292A/en not_active IP Right Cessation
-
2014
- 2014-08-03 IL IL233928A patent/IL233928A0/en unknown
-
2015
- 2015-03-24 HK HK15103009.6A patent/HK1202432A1/zh unknown
- 2015-10-15 HK HK15110097.4A patent/HK1209455A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1209455A1 (zh) | 2016-04-01 |
| WO2013116505A1 (en) | 2013-08-08 |
| GB201414403D0 (en) | 2014-10-01 |
| EP2809775A4 (en) | 2015-07-01 |
| IL233928A0 (en) | 2014-09-30 |
| US20150064217A1 (en) | 2015-03-05 |
| CN104540937A (zh) | 2015-04-22 |
| NZ628292A (en) | 2016-09-30 |
| EP2809775A1 (en) | 2014-12-10 |
| CA2863653A1 (en) | 2013-08-08 |
| AU2013215116A1 (en) | 2014-08-21 |
| HK1202432A1 (zh) | 2015-10-02 |
| JP2015506698A (ja) | 2015-03-05 |
| EP2809775B1 (en) | 2018-06-13 |
| WO2013116541A1 (en) | 2013-08-08 |
| GB2512558A (en) | 2014-10-01 |
| KR20140143361A (ko) | 2014-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207962A1 (zh) | 分枝桿菌抗原疫苗 | |
| HK1207967A1 (zh) | 疫苗 | |
| HK1204302A1 (zh) | 癌症免疫療法的組合物和方法 | |
| EP2714073A4 (en) | ANTI-CANCER ANTIGEN GENE VACCINE IN SITU | |
| LT2714071T (lt) | Individualizuotos vakcinos nuo vėžio | |
| EP2876161A4 (en) | VACCINE | |
| GB201223386D0 (en) | Vaccine | |
| EP2868325A4 (en) | TRANSDERMAL PREPARATION OF ANTIGENIC PEPTIDE ASSOCIATED WITH CANCER | |
| SG11201500396TA (en) | Tumor vaccination | |
| HK1201176A1 (zh) | 抗原呈遞癌症疫苗 | |
| GB201003293D0 (en) | Cancer vaccine | |
| HK1209455A1 (zh) | 多能胚層起源抗原呈遞癌症疫苗 | |
| HK1202070A1 (zh) | 用於腫瘤免疫療法的疫苗 | |
| EP2869828A4 (en) | SAFE IMMUNOTHERAPY | |
| ZA201407309B (en) | Antigens and antigen combinations | |
| ME03498B (me) | Individualizovane vakcine protiv kancera | |
| GB201202090D0 (en) | Vaccine | |
| GB201107549D0 (en) | Cancer vaccine | |
| GB201217321D0 (en) | Vaccine | |
| GB201210226D0 (en) | Vaccine | |
| GB201206169D0 (en) | Vaccine | |
| GB201205599D0 (en) | Vaccine | |
| GB201207385D0 (en) | Antigens and antigen combinations | |
| GB201207383D0 (en) | Antigens and antigen combinations | |
| GB201216749D0 (en) | Antigen combinations |